Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems

Clinical Cancer Research

Volumn 17, Issue 8, 2011, Pages 2339-2349

  More, Swati S ^a   Itsara, Melissa ^a   Yang, Xiaodong ^b   Geier, Ethan G ^a   Tadano, Michelle K ^a   Seo, Youngho ^c   Van Brocklin, Henry F ^c   Weiss, William A ^a   Mueller, Sabine ^a   Haas Kogan, Daphne A ^b   Du Bois, Steven G ^b   Matthay, Katherine K ^b   Giacomini, Kathleen M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; MESSENGER RNA; NORADRENALIN TRANSPORTER; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG POTENTIATION; DRUG TISSUE LEVEL; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION;

3-IODOBENZYLGUANIDINE; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NEUROBLASTOMA; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; RADIOPHARMACEUTICALS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 79954620898     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2949     Document Type: Article

References (29)

1. Goodman MT, Gurney JG, Smith MA, Olshan AF. Sympathetic nervous system tumors. In: Ries LA, Smith MA, Gurney JG, et al. editors. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program, 1975-1995. Bethesda, MD: National Cancer Institute; 1999. p. 65-72.
2. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010;362:2202-11.
3. DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 1999;21:181-9. (Pubitemid 30306028)
4. Takeda N. Simultaneous analyses of monoamines and their metabolites in urine specimens of patients with neuroblastoma. Comp Biochem Physiol C 1993;105:373-7. (Pubitemid 23259066)
5. Hadrich D, Berthold F, Steckhan E, Bönisch H. Synthesis and characterization of fluorescent ligands for the norepinephrine transporter: potential neuroblastoma imaging agents. J Med Chem 1999;42:3101-8. (Pubitemid 29384045)
6. Taggart D, Dubois S, Matthay KK. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging 2008;52:403-18.
7. DuBois SG, Matthay KK. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol 2008;35(Suppl. 1):S35-48.
8. Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 2007;25:1054-60. (Pubitemid 46596756)
9. Gediya LK, Chopra P, Purushottamachar P, Maheshwari N, Njar VC. A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells. J Med Chem 2005;48:5047-51. (Pubitemid 41033145)
10. 2. J Med Chem 2007;50:6725-9. (Pubitemid 350309111)
11. Bayer M, Kuçi Z, Schömig E, Gründemann D, Dittmann H, Handgretinger R, et al. Uptake of MIBG and catecholamines in noradrenaline and organic cation transporter-expressing cells: potential use of corticosterone for a preferred uptake in neuroblastoma-and pheochromocytoma cells. Nucl Med Biol 2009;36:287-94.
12. Mandel SJ, Shankar LK, Benard F, Yamamoto A, Alavi A. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med 2001;26:6-9. (Pubitemid 32003174)
13. Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J, et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol 2010;28:3623-9.
14. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-31. (Pubitemid 46218695)
15. Gourand F, Mercey G, Ibazizéne M, Tirel O, Henry J, Levacher V, et al. Chemical delivery system of metaiodobenzylguanidine (MIBG) to the central nervous system. J Med Chem 2010;53:1281-7.
16. 131I-metaiodobenzylguanidine (MIBG) and 123I-MIBG: Clinical implications of the use of 123I-MIBG. Med Ped Oncol 1987;15:170-7. (Pubitemid 18025972)
17. Hoefnagel CA, Voute PA, De Kraker J, Marcuse HR. Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J Nucl Med 1987;28:308-14. (Pubitemid 17049463)
18. 131I-meta-iodo- benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study. Eur J Cancer 1998;34:1398-402. (Pubitemid 28370932)
19. Harms KL, Chen X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res 2007;67:3145-52. (Pubitemid 46724851)
20. De Los Santos M, Zambrano A, Aranda A. Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SHSY5Y cells. Mol Cancer Ther 2007;6:1425-32. (Pubitemid 46712006)
21. Camphausen K, Tofilon PJ. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol 2007;25:4051-6. (Pubitemid 47492949)
22. Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM. Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 2005;62:223-9. (Pubitemid 40591946)
23. Flatmark K, Nome RV, Folkvord S, Bratland A, Rasmussen H, Ellefsen MS, et al. Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition. Radiat Oncol 2006;1:25.
24. Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, Meyn RE. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 2006;5:1967-74. (Pubitemid 44336568)
25. Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 2005;20:195-9. (Pubitemid 40696102)
26. Corvi R, Savelyeva L, Schwab M. Patterns of oncogene activation in human neuroblastoma cells. J Neurooncol 1997;31:25-31. (Pubitemid 27077706)
27. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264-79. (Pubitemid 29318861)
28. Bell E, Chen L, Liu T, Marshall GM, Lunec J, Tweddle DA. MYCN oncoprotein targets and their therapeutic potential. Cancer Lett 2010;293:144-57.
29. 131I-MIBG) therapy for neuroblastoma. Pediatr Blood Cancer 2011;56:191-201.